Facebook Pixel Code
About Sickkids
About SickKids

Sylvain Baruchel, MD

The Hospital for Sick Children
Senior Medical Advisor, Innovative Therapeutic Trials
Paediatrics

Research Institute
Senior Associate Scientist, Emeritus
Research Institute

University of Toronto
Professor, Emeritus
Paediatrics


Phone: 416-813-7795
Fax: 416-813-5327
e-mail: sylvain.baruchel@sickkids.ca

Brief Biography

Dr. Baruchel received his MD degree in 1977 from the Rene Descartes University in Paris and was recruited to the Haematology/Oncology Division at the Montreal Children's Hospital in Canada in 1988 where he was Director of the Sickle Cell/Thalassemia Comprehensive Care Programs and Medical Coordinator of the Hematology/Oncology Inpatient Unit.

In 1996, Baruchel was recruited to The Hospital for Sick Children in Toronto where he is currently a member of the Solid Tumour Section in the Division of Haematology/Oncology, as well as Director of the New Agent and Innovative Therapy Program. Baruchel was the Principal Investigator for the Institution's participation in the Phase 1 consortium of the Children's Oncology Group (COG). Baruchel’s laboratory serves as a reference laboratory for COG clinical trials related to angiogenesis. 

Baruchel is the Chair of the Canadian pediatric phase 1 consortium under the hospice of the National Cancer Institute of Canada, Clinical Trials Group. Baruchel also initiated the James Birrell fund at The Hospital for Sick Children, a fundraising initiative dedicated to neuroblastoma research.

Baruchel developed and led the innovative Tip of the Toes Foundation, an organization dedicated to the promotion of outdoor expeditions and other nature-oriented experiences for children and adolescents with cancer in order to foster their self-esteem and self-confidence. In the summer of 2000, the expedition sponsored a millennium project entitled "Life is Beautiful" that brought teenagers with cancer from across the country to Nunavut with the final destination being Ellesmere National Park.

In 2010, Baruchel was awarded the Légion D'honneur (equivalent to the Order of Canada) from the French government for his work done in the last ten years in the field of rehabilitation and increasing self-esteem in childhood cancer and more importantly for philanthropic activity, fundraising, and developing the concept of Adventure Therapy.

Baruchel was elected Chair of the Advances in Neuroblastoma Research (ANR) 2012 meeting which will be held in Toronto, June 18-21, 2012. ANR is the annual international symposium dedicated to preclinical and clinical research in neuroblastoma. Every two years, the meeting brings together 700 researchers from around the world who focus on neuroblastoma research. This will be one of the major international events in paediatric oncology in 2012.

Baruchel has been a leader in clinical trials in oncology at SickKids as the director of the clinical trial program for 20 years and also developed the “New Agent and Innovative Therapy Program” here at SickKids. Baruchel is nationally and internationally recognized for his work in oncology drug development. He is the founder and former chair of the Canadian C17 developmental therapeutic network and current chair of the National Cancer Institute of Canada Paediatric Investigational New Drug committee.

His current role collaborates with Dr. Rulan Parekh, the Associate Chair of Clinical Research in leading and developing the infrastructure and processes needed to implement and conduct SickKids sponsored innovative therapeutic trials using novel agents, or devices throughout SickKids.

Baruchel is also leading a working group within the Clinical Research Secretariat, an advisory group on clinical research, to develop a pipeline for clinical trials and acts as a resource for Principal Investigators looking at early phase trial development.

Research Interests

  • Angiogenesis.
  • Clinical pharmacology.
  • Experimental therapies in children with cancer and serious blood disorders.
  • Phase I & Phase II clinical trials.
  • Surrogate markers.
  • Preclinical targeted radio-therapy.

Publications

Click here for a list of publications.